The anticipation surrounding dose optimization data for Pfizer (NYSE:PFE)'s obesity treatment, danuglipron, was also mentioned as a point of interest for the first quarter. However, the analyst ...
In a report released today, Elmar Kraus from DZ BANK AG maintained a Buy rating on Pfizer (PFE – Research Report). The company’s shares opened ...
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows ...
Dividend stocks have remained a focal point for investors, especially amid market volatility and the growing need for steady ...
Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...
PFS Partners LLC lowered its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 11.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange ...
Pfizer ( PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...
Despite a significant year-over-year decline in Comirnaty revenue, the overall performance was strong, driven by growth in non-COVID-19 products and strategic acquisitions. Pfizer, a renowned ...
Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback